Bridgeway Capital Management’s Design Therapeutics DSGN Stock Holding History

Bridgeway Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$391K	Sell	27,000 -25,000	-48%	-$312K	0.01%	908
2026 Q1	$553K	Sell	52,000 -26,500	-34%	-$268K	0.01%	802
2025 Q4	$736K	Sell	78,500 -109,700	-58%	-$859K	0.02%	757
2025 Q3	$1.42M	Hold	188,200	–	–	0.03%	642
2025 Q2	$634K	Buy	188,200 +74,400	+65%	+$278K	0.02%	731
2025 Q1	$439K	Sell	113,800 -14,600	-11%	-$69.7K	0.01%	766
2024 Q4	$792K	Sell	128,400 -107,200	-46%	-$621K	0.02%	716
2024 Q3	$1.27M	Hold	235,600	–	–	0.03%	624
2024 Q2	$789K	Buy	235,600 +89,700	+61%	+$349K	0.02%	751
2024 Q1	$588K	Hold	145,900	–	–	0.01%	878
2023 Q4	$387K	Buy	145,900 +65,400	+81%	+$150K	0.01%	1004
2023 Q3	$190K	Buy	+80,500	New	+$375K	﹤0.01%	1112

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bridgeway Capital Management's DSGN Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Design Therapeutics (DSGN) stake by 48% in Q2 2026, selling an estimated $312K and leaving 27,000 shares worth $391K. The position accounts for 0.01% of the portfolio, ranked #908.

Bridgeway Capital Management first reported a position in DSGN in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.42M in Q3 2025. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Bridgeway Capital Management held 27,000 shares of Design Therapeutics worth $391K as of Q2 2026.
Bridgeway Capital Management sold 25,000 Design Therapeutics shares in Q2 2026, an estimated $312K.
Design Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #908 holding.
Bridgeway Capital Management first reported a position in Design Therapeutics in Q3 2023 and has held it in 12 quarters since.
Bridgeway Capital Management's Design Therapeutics position peaked at $1.42M in Q3 2025.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.